Key signaling pathways and targets in lung cancer therapy.
Despite the use of chemotherapy, radiation therapy, and surgery, the overall outcome for lung cancer continues to be disappointing. In order to make a difference in the treatment of lung cancer, novel therapeutics need to be developed. The molecular mechanisms of carcinogenesis in lung cancer are complex and involve multiple oncogenes, tumor suppressor genes, receptor tyrosine kinases, cytoplasmic enzymes, and tumor interstitial elements, among other cellular proteins. In this review, the authors discuss key signaling pathways and molecular targets in the treatment of lung cancer. Through understanding molecular targets and the utilization of specific inhibitors, hopefully, a dramatic impact will be made in the biology and therapy of lung cancer.
Choong
Nicholas W
NW
Section of Hematology/Oncology, University of Chicago Medical Center, IL 60615, USA.
Salgia
Ravi
R
Vokes
Everett E
EE
D000818:Animals; D066246:ErbB Receptors / Q000502:physiology; D016147:Genes, Tumor Suppressor / Q000502:physiology; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics* / Q000503:physiopathology* / Q000628:therapy*; D009857:Oncogenes / Q000502:physiology; D011505:Protein-Tyrosine Kinases / Q000502:physiology; D015398:Signal Transduction / Q000502:physiology*
D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases